A study with sofosbuvir and ribavirin for adolecents and children with chronic Hepatitis C infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-002283-32

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the PK Lead-in Phase of this study is: *To evaluate the steady state pharmacokinetics (PK) and confirm the dose of sofosbuvir (SOF) in HCV-infected pediatric subjects The primary objectives of the Treatment Phase of this study are: *To evaluate the safety and tolerability of SOF + RBV for 12 or 24 weeks in HCV-infected pediatric subjects with genotype (GT) GT-2 or GT-3, respectively


Critère d'inclusion

  • Chronic hepatitis C virus infection